Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Explore U.S. economic trends: growth uncertainty and rising inflation risks.

The RBA’s proposed surcharge ban and fee caps may reshape payments, but Visa and Mastercard are already positioned for the ...

Over the last 12 months to 30 June 2025, Bloomberg data revealed that CBA alone accounted for 33% of the S&P/ASX 200’s total ...

Greg Sharenow, managing director and portfolio manager, charts the continued resilience of commodities and their low ...

Australian bonds experienced a resurgence, posting their best financial year since 2018/19. Some managers returned close to ...

In a market full of flashy tech and speculative growth stories, here's a refreshingly grounded stock to watch.

ARK strives to invest at the pace of innovation. The ARK Global Disruptive Innovation Fund aims to achieve a target average ...

Rational investors have abandoned CBA, resulting in a share price that gets 'pushed around' by passive and momentum flows.

By learning to avoid mistakes you can improve your returns as much by learning what qualities to look for in a business.

While markets chase the AI hype, medtech quietly trades at decade-lows. Here’s why that’s an opportunity for long-term ...

In this wire, we crunch the data on the country's top-performing Aussie equities funds for FY25 and examine their positioning ...